Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
GLP-1 receptor agonists, once used primarily for type 2 diabetes management, are now central to how physicians approach metabolic health and weight management
2024 DOI: 10.1038/s41421-024-00702-y PMID: 39019866 Read on PubMed European Journal of Clinical Pharmacology A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity Kaur M, Misra S 2024 DOI: 10.1007/s00228-024-03646-0 PMID: 38367045 Read on PubMed Cardiology in Review The First Triple Agonist for Antiobesity: Retatrutide Tetelbaum L, Mullally JA, Frishman WH 2024 DOI: 10.1097/CRD.0000000000000793 PMID: 39724554 Read on PubMed NPJ Metabolic Health and Disease Incretin triple agonist retatrutide alleviates obesity-associated cancer progression Marathe SJ, Grey EW, Bohm MS, et al
Lttl GLP-1 Consumer Research 2026: Could Dose-Stable Pricing Make Telehealth Costs Easier to Plan
In addition to its primary use, Ozempic has gained popularity for its ability to facilitate weight loss in individuals with obesity or overweight
US$ 27.17
US$ 26.00
US$ 29.50
US$ 26.74
US$ 23.39
US$ 24.24
US$ 28.45
